ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts rate ICU Medical “Moderate Buy.” The consensus comes from nine analysts—four buys, two strong buys, and three holds—with an average 12-month price target of $192.80.
• Several brokerages raised their price targets, including Piper Sandler to $195, Needham to $187, KeyCorp to $182, and Raymond James at $200, despite Sanford C. Bernstein downgrading the stock to “market perform.”
• ICU Medical exceeded quarterly expectations, reporting $2.37 in EPS versus the $1.91 consensus and $547.88 million in revenue versus $533.44 million expected. Shares opened at $159.38, while insiders sold approximately $3.9 million of stock during the last quarter.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $192.80.

Several brokerages have recently commented on ICUI. Sanford C. Bernstein downgraded ICU Medical to a "market perform" rating in a report on Monday, June 15th. Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Piper Sandler increased their target price on shares of ICU Medical from $163.00 to $195.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. KeyCorp increased their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an "overweight" rating in a report on Tuesday, July 21st. Finally, Raymond James Financial restated a "strong-buy" rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $159.38 on Monday. ICU Medical has a 52 week low of $112.50 and a 52 week high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $169.13 and a 200-day simple moving average of $147.28. The company has a market cap of $3.98 billion, a P/E ratio of 135.07, a P/E/G ratio of 2.01 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period in the prior year, the company posted $2.10 EPS. ICU Medical's quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts forecast that ICU Medical will post 7.22 EPS for the current year.

Insider Buying and Selling at ICU Medical

In related news, Director Elisha W. Finney sold 378 shares of ICU Medical stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company's stock, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total transaction of $819,158.64. Following the transaction, the vice president directly owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,830 shares of company stock valued at $3,905,003 over the last quarter. Company insiders own 2.10% of the company's stock.

Institutional Trading of ICU Medical

Hedge funds have recently made changes to their positions in the business. Versant Capital Management Inc grew its stake in shares of ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier's stock valued at $50,000 after acquiring an additional 65 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of ICU Medical in the second quarter valued at approximately $3,744,000. Allworth Financial LP boosted its stake in shares of ICU Medical by 155.1% in the second quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 107 shares during the period. Arizona State Retirement System increased its stake in ICU Medical by 1.7% during the 2nd quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier's stock worth $960,000 after acquiring an additional 109 shares during the period. Finally, Nykredit A S acquired a new position in ICU Medical in the 2nd quarter valued at $135,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company's product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.